Linda N. Liu
Keine laufenden Positionen mehr
Profil
Linda N.
Liu worked as a Senior Director at MaxCyte, Inc. from 2000 to 2007.
She then worked as an Executive Director at Amplimmune, Inc. from 2007 to 2015.
Prior to that, she worked as a Senior Scientist at Osiris Therapeutics, Inc. from 1999 to 2000.
Currently, she is working as a Senior Vice President at NextCure, Inc. since 2015.
Dr. Liu completed her undergraduate degree from Wuhan University and her doctorate from The University of Texas at Austin.
Ehemalige bekannte Positionen von Linda N. Liu
| Unternehmen | Position | Ende |
|---|---|---|
| NEXTCURE, INC. | Chief Tech/Sci/R&D Officer | 01.02.2022 |
Amplimmune, Inc.
 Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01.08.2015 |
| MAXCYTE, INC. | Corporate Officer/Principal | 01.01.2007 |
| OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2000 |
Ausbildung von Linda N. Liu
| Wuhan University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| NEXTCURE, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Health Technology |
